GlassScriptPhysician profile
Amanda Dawn Fox
NPI 1336791672
$2,704.51
in general payments reported to CMS, 2019-2025
21 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $315 · 2022: $177 · 2023: $1,238 · 2024: $658 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $580.74 | 2022-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $539.32 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Infinion 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $519.30 | 2023-2025 | Relistor |
| Medtronic, INC. | $253.50 | 2022-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Nevro Corp. | $139.03 | 2024 | Senza |
| Esperion Therapeutics, INC. | $126.80 | 2021-2022 | |
| Amarin Pharma, INC. | $107.18 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $83.34 | 2024-2025 | |
| Novo Nordisk INC | $63.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.25 | 2021 | |
| Scilex Pharmaceuticals INC. | $47.64 | 2025 | |
| Abbvie INC. | $33.75 | 2022-2023 | |
| Tonix Medicines, INC. | $28.72 | 2025 | Tonmya |
| Si-Bone, INC. | $24.23 | 2024 | |
| Bioventus LLC | $19.54 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $18.75 | 2022 | |
| Averitas Pharma INC. | $17.63 | 2024 | Qutenza |
| Curonix LLC | $13.61 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceutical Holding Company LTD. | $13.12 | 2022 | |
| Pfizer INC. | $13.02 | 2021 | |
| Hikma Pharmaceuticals USA | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.